Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
35.21
+3.59 (11.35%)
Apr 29, 2026, 12:45 PM EDT - Market open
Teva Pharmaceutical Revenue
In the year 2025, Teva Pharmaceutical had annual revenue of $17.26B with 4.32% growth. Teva Pharmaceutical had revenue of $4.71B in the quarter ending December 31, 2025, with 11.40% growth.
Revenue (ttm)
$17.26B
Revenue Growth
+4.32%
P/S Ratio
2.13
Revenue / Employee
$508,336
Employees
33,950
Market Cap
41.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.26B | 714.00M | 4.32% |
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 28.48B |
| Haleon | 14.85B |
| Viatris | 14.30B |
| Zoetis | 9.47B |
| Elanco Animal Health | 4.72B |
| Dr. Reddy's Laboratories | 3.85B |
| United Therapeutics | 3.18B |
| Neurocrine Biosciences | 2.86B |
TEVA News
- 5 hours ago - Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand - Reuters
- 5 hours ago - Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution - GlobeNewsWire
- 6 hours ago - Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy - GlobeNewsWire
- 1 day ago - Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock. - The Motley Fool
- 11 days ago - 3 Catalysts That Could Send Teva Stock to $40 and Beyond - The Motley Fool
- 14 days ago - Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners - GlobeNewsWire
- 15 days ago - Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics - GlobeNewsWire
- 4 weeks ago - Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) - GlobeNewsWire